STERIS plc
NYSE:STE
Intrinsic Value
STERIS Plc engages in the provision of healthcare and life science product and service solutions. [ Read More ]
The intrinsic value of one STE stock under the Base Case scenario is 221.92 USD. Compared to the current market price of 224.82 USD, STERIS plc is Overvalued by 1%.
Valuation Backtest
STERIS plc
Run backtest to discover the historical profit from buying and selling STE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
STERIS Reports Strong Q3 Performance
2024-Q3 Earnings Call
STERIS demonstrated a robust Q3, with a 10% surge in constant currency organic revenue stemming from increased volume and a 2.7% boost in price. Gross margin edged up by 0.5% to 43.6%, outweighing material and labor inflation as well as currency headwinds, but EBIT margin dipped by 0.8% to 23.1%. The Healthcare segment spearheaded growth, overshadowing softened demand in other divisions. A mix shift from the AST segment to Healthcare influenced the earnings landscape and is expected to persist. Net income hit $220.9 million, with capital expenditures marking $268.8 million and free cash flow reaching $457 million. Entering fiscal 2024, STERIS forecasts total revenue growth of 10-11%, with constant currency organic growth at 7-8%, and projects adjusted EPS between $8.60 and $8.70.
Balance Sheet Decomposition
STERIS plc
Current Assets | 2.2B |
Cash & Short-Term Investments | 195.6m |
Receivables | 964m |
Other Current Assets | 1.1B |
Non-Current Assets | 9.2B |
PP&E | 2B |
Intangibles | 7.1B |
Other Non-Current Assets | 77.3m |
Current Liabilities | 913.7m |
Accounts Payable | 276.7m |
Accrued Liabilities | 381.1m |
Other Current Liabilities | 255.9m |
Non-Current Liabilities | 4.1B |
Long-Term Debt | 3.2B |
Other Non-Current Liabilities | 875m |
Earnings Waterfall
STERIS plc
Revenue
|
5.4B
USD
|
Cost of Revenue
|
-3B
USD
|
Gross Profit
|
2.4B
USD
|
Operating Expenses
|
-1.5B
USD
|
Operating Income
|
846.9m
USD
|
Other Expenses
|
-280m
USD
|
Net Income
|
566.8m
USD
|
Free Cash Flow Analysis
STERIS plc
What is Free Cash Flow?
STE Profitability Score
Profitability Due Diligence
STERIS plc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
STERIS plc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
STE Solvency Score
Solvency Due Diligence
STERIS plc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
STERIS plc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
STE Price Targets Summary
STERIS plc
According to Wall Street analysts, the average 1-year price target for STE is 245.24 USD with a low forecast of 217.15 USD and a high forecast of 278.25 USD.
Ownership
STE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
STE Price
STERIS plc
Average Annual Return | 12.93% |
Standard Deviation of Annual Returns | 24.2% |
Max Drawdown | -36% |
Market Capitalization | 22.2B USD |
Shares Outstanding | 99 354 000 |
Percentage of Shares Shorted | 2.84% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
STERIS Plc engages in the provision of healthcare and life science product and service solutions. The firm offers a mix of consumable products, such as detergents, gastrointestinal (GI) endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, dental instruments and tools, instrument and scope repair solutions, laboratory testing services, outsourced reprocessing, and capital equipment products, such as sterilizers and surgical tables, automated endoscope reprocessors, and connectivity solutions such as operating room (OR) integration. The firm operates through four reportable business segments: Healthcare, Applied Sterilization Technologies, Life Sciences and Dental. Its Healthcare segment focused on sterile processing departments and procedural centers, such as operating rooms, endoscopy suites, and renal dialysis centers.
Contact
IPO
Employees
Officers
The intrinsic value of one STE stock under the Base Case scenario is 221.92 USD.
Compared to the current market price of 224.82 USD, STERIS plc is Overvalued by 1%.